SynthesisFrontiers in clinical diabetes and healthcare2024
Metabolic syndrome among type 2 Diabetes Mellitus patients in Ethiopia: a systematic review and meta-analysis.
Synthesis in Frontiers in clinical diabetes and healthcare, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prevalence of hyperuricemia among patients with non-communicable diseases in Ethiopia: a systematic review and meta-analysis.Cardiovascular diabetology. Endocrinology reports · 2026Review
- Influence of Age and Sex on the Clinical Profile of Metabolic Syndrome in Diabetic Patients.Cureus · 2025Article
- Pharmacogenetic Predictors of Metformin Response in Metabolic Syndrome and Type 2 Diabetes: Evidence from a Cohort Study in Kazakhstan.Journal of diabetes research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: The prevalence of metabolic syndrome among type 2 diabetes mellitus patients was inconsistent in Ethiopia. Therefore, we aimed to pool the prevalence of metabolic syndrome among type 2 diabetes mellitus patients using a systematic review and meta-analysis. Methods: PubMed, EMBASE, and Cochrane Library databases were systematically searched for relevant articles from January 2023 to January 2024. In addition, a manual search was conducted using published articles' reference lists. The random-effects model was used to pool prevalence from individual studies. All analysis was performed using R software. Results: A total of nine articles met the inclusion criteria and were included in the analysis. The participants' average age was 59.8 ± 3.84 years old. The pooled prevalence of MetS in T2DM patients was 53% (95% CI: 47-58). A significant heterogeneity was found across the included studies (P < 0.001, I2 = 92%). Based on diagnostic criteria, the prevalence of MetS in T2DM patients was 49% (95% CI: 43-56), 57% (95% CI: 47-67), 57% (95% CI: 43-77), and 44% (95% CI: 20-58) based on IDF, NCEP-ATP II, 2009 harmonized, and WHO criteria. By gender, the prevalence of MetS in T2DM patients was 48% (95% CI: 28-68) for females and 32% (95% CI: 17-49) for males. Conclusion: This study found that over half of type 2 diabetes mellitus patients in Ethiopia are affected by metabolic syndrome, with a higher prevalence observed in females compared to males. The NCEP-ATP II and 2009 harmonized criteria consistently yielded similar prevalence rates of metabolic syndrome. These findings highlight the importance of educating T2DM patients on preventing and managing cardiovascular disease and its related complications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.